Profil
Valerie Estess was the founder of ProJenX, Inc. and held the title of Director.
Postes actifs de Valerie Estess
| Sociétés | Poste | Début |
|---|---|---|
ProJenX, Inc.
 ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
ProJenX, Inc.
ProJenX, Inc. Miscellaneous Commercial ServicesCommercial Services ProJenX, Inc. is a clinical-stage biotechnology company that focuses on developing targeted therapies for untreatable brain diseases, with a particular emphasis on ALS. The company is based in Nissequogue, NY. ProJenX's lead therapy candidate, Prosetin, is a first-in-class kinase inhibitor that is being developed for people living with ALS. The company's innovative, patient-specific, cell-based drug discovery platform is at the heart of its approach to research and drug development for ALS and other debilitating brain diseases. The company was founded in 2021 by Erin Fleming and Valerie Estess, and the CEO is Stan E. Abel. | Commercial Services |
